Efficacy of Colchicine in the Treatment of Patients With Coronary Artery Disease: A Mini-Review

Purpose: This review of colchicine, an effective anti-inflammatory agent, examines whether the reduction in ischemic events produced by colchicine translates to a reduction in mortality, the optimal duration of treatment, and the patient populations that benefits the most from colchicine treatment.Methods: We performed a comprehensive PubMed database search using the key words colchicine and coronary heart disease on August 23, 2021. We also screened the included reference list of manuscripts.Findings: Colchicine's role in the secondary pre-vention of coronary artery disease has been the focus of recent large-scale randomized controlled trials in chronic coronary syndrome (ie, the Low-Dose Colchicine and Low-Dose Colchicine 2 trials), acute myocardial infarction (the Colchicine Cardiovascular Outcomes Trial and Colchicine in Patients With Acute Coronary Syndrome trial), and after percutaneous coronary intervention (the Colchicine-Percutaneous Coronary Intervention trial).Implications: Current evidence suggests that low -dose colchicine (0.5 mg once a day) reduces the risk of cardiovascular events among patients with acute myocardial infarction or chronic coronary syndrome. Colchicine has the potential to become a new standard therapy for the prevention of coronary artery disease-related atherothrombotic events because it is effective and cost-efficient and has a well -tolerated safety profile. (Clin Ther. 2022;44:1150- 1159.)(c) 2022 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC -ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )

Automated summary

This review examines the use of colchicine as an effective anti-inflammatory agent and its impact on ischemic events and mortality reduction. The study suggests that low-dose colchicine has the potential to become a new standard therapy for the prevention of coronary artery disease-related atherothrombotic events.